[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2015KN00323A - - Google Patents

Info

Publication number
IN2015KN00323A
IN2015KN00323A IN323KON2015A IN2015KN00323A IN 2015KN00323 A IN2015KN00323 A IN 2015KN00323A IN 323KON2015 A IN323KON2015 A IN 323KON2015A IN 2015KN00323 A IN2015KN00323 A IN 2015KN00323A
Authority
IN
India
Prior art keywords
preparation
umeclidinium bromide
processes
relates
present
Prior art date
Application number
Inventor
Frank Hossner
John Bryce Strachan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2015KN00323A publication Critical patent/IN2015KN00323A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to a process for the preparation of umeclidinium bromide, and to processes for preparing intermediates used in the preparation of umeclidinium bromide.
IN323KON2015 2012-08-15 2013-08-14 IN2015KN00323A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261683369P 2012-08-15 2012-08-15
PCT/EP2013/067035 WO2014027045A1 (en) 2012-08-15 2013-08-14 Chemical process

Publications (1)

Publication Number Publication Date
IN2015KN00323A true IN2015KN00323A (en) 2015-07-10

Family

ID=49080842

Family Applications (1)

Application Number Title Priority Date Filing Date
IN323KON2015 IN2015KN00323A (en) 2012-08-15 2013-08-14

Country Status (12)

Country Link
US (2) US9273001B2 (en)
EP (2) EP3401316B1 (en)
JP (2) JP6389174B2 (en)
KR (1) KR20150043465A (en)
CN (2) CN104619706B (en)
AU (3) AU2013304102B2 (en)
BR (1) BR112015003101B1 (en)
CA (1) CA2881935A1 (en)
ES (2) ES2678697T3 (en)
IN (1) IN2015KN00323A (en)
RU (1) RU2644160C2 (en)
WO (1) WO2014027045A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4252742A3 (en) 2014-05-28 2023-12-27 GlaxoSmithKline Intellectual Property Development Ltd Fluticasone furoate in the treatment of copd
US10023535B2 (en) 2014-11-03 2018-07-17 Olon S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
PT108370B (en) 2015-03-30 2018-10-25 Hovione Farm S A ACLIDINE BROMETON PREPARATION PROCESS
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
PT109740B (en) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa PROCESS FOR THE PREPARATION OF UMECLIDINUM BROMIDE
CN108069956B (en) * 2016-11-18 2021-03-16 扬州奥锐特药业有限公司 1-azabicyclo [2,2,2] oct-4-yl phenyl ketone compound, preparation method and application thereof
IT201700058796A1 (en) * 2017-05-30 2018-11-30 Olon Spa Procedure for the preparation of a new intermediate of synthesis of umeclidinium.
CN107935917A (en) * 2017-10-30 2018-04-20 广东莱佛士制药技术有限公司 A kind of synthetic method of 1 (2 chloroethyl) 4 piperidinecarboxylic acid ester
CN109956938A (en) * 2017-12-26 2019-07-02 天津金耀集团有限公司 Wumei bromine ammonium intermediate crystal form and preparation method thereof and the method that Wumei bromine ammonium is prepared with the intermediate
CN108558860B (en) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 Method for synthesizing umeclidinium bromide
PT115583B (en) * 2019-06-17 2022-05-02 Hovione Farm S A CONTINUOUS PROCESS FOR THE PREPARATION OF ANTICHOLINERGIC DRUGS
PT117440B (en) 2021-09-03 2024-04-26 Hovione Farm S A PROCESS FOR THE PREPARATION OF CHLOROAQUIL SUBSTITUTED CYCLIC AMINES
CN117310022B (en) * 2023-09-22 2024-05-17 山东泰合医药科技有限公司 Method for separating and detecting related substances of quinuclidine benzhydrol as intermediate of ubenimex

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998832A (en) * 1975-04-16 1976-12-21 G. D. Searle & Co. Anti-diarrheal compounds
US4540780A (en) * 1983-06-02 1985-09-10 Warner-Lambert Company Diphenylmethylene piperidines
FR2816618B1 (en) * 2000-11-15 2002-12-27 Aventis Pharma Sa HETEROCYCLYLALCOYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
TWI363759B (en) * 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
JP4841279B2 (en) * 2006-03-23 2011-12-21 一般財団法人 化学物質評価研究機構 Method for predicting carcinogenicity of test substance
WO2011029896A1 (en) * 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
US8846647B2 (en) * 2011-01-31 2014-09-30 Bristol-Myers Squibb Company C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity

Also Published As

Publication number Publication date
CA2881935A1 (en) 2014-02-20
AU2013304102B2 (en) 2016-09-01
CN104619706A (en) 2015-05-13
AU2016213768A1 (en) 2016-09-01
US20160159786A1 (en) 2016-06-09
JP6799037B2 (en) 2020-12-09
US20150232423A1 (en) 2015-08-20
EP2885298A1 (en) 2015-06-24
WO2014027045A1 (en) 2014-02-20
JP2015524832A (en) 2015-08-27
RU2015104269A (en) 2016-10-10
ES2893473T3 (en) 2022-02-09
AU2013304102A1 (en) 2015-02-26
ES2678697T3 (en) 2018-08-16
JP2018203752A (en) 2018-12-27
CN107163038A (en) 2017-09-15
CN104619706B (en) 2017-06-20
EP3401316B1 (en) 2021-08-04
US9273001B2 (en) 2016-03-01
RU2644160C2 (en) 2018-02-08
EP3401316A1 (en) 2018-11-14
BR112015003101A2 (en) 2017-07-04
EP2885298B1 (en) 2018-06-13
US9657011B2 (en) 2017-05-23
AU2016262787A1 (en) 2016-12-15
JP6389174B2 (en) 2018-09-12
CN107163038B (en) 2020-07-28
KR20150043465A (en) 2015-04-22
AU2016213768B2 (en) 2018-01-04
BR112015003101B1 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
IN2015KN00323A (en)
PH12018501094A1 (en) Process for the preparation of an apoptosis-inducing agent
MX2015002487A (en) Process for the preparation of teneligliptin.
EP2938616A4 (en) The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
EA033455B1 (en) Crystalline forms of substituted 5-fluoro-1h-pyrazolopyridines, processes for preparing same, use thereof for producing a medicament, medicament and method of treatment based thereof
SG11201406833PA (en) Catalyst for production of butadiene, process for producing the catalyst, and process for producing butadiene using the catalyst
MX2015006915A (en) Preparation of a stable beverage.
MX2013007567A (en) Process for preparing polyesteretherols.
MX369662B (en) Microalgal flour granules and process for preparation thereof.
NZ704103A (en) Process for the preparation of 4-amino-5-fluoro-3-halo-6-(substituted)picolinates
IN2014DN09798A (en)
IN2013MU03070A (en)
IN2013MU01113A (en)
NZ704104A (en) Fluoropicolinoyl fluorides and processes for their preparation
MX2015003034A (en) Syringe containing a composition, especially a pharmaceutical composition, comprising immunoglobins, method for the production thereof and use of same.
MX2012010317A (en) β-hydroxyalkylamides, method for their production and use thereof.
MX350122B (en) Disperse dyes, their preparation and their use.
IN2015DN00725A (en)
MX360870B (en) Catalysts for producing cast polyamide, method for the production of said catalysts and the use thereof.
MX2014003936A (en) Method for producing dithiine tetracarboximides.
MY167578A (en) Novel cheese and method for producing the same
MX2015011881A (en) Process for the preparation of 3,7-dimethylnonan-1-ol.
EP2886548A4 (en) Method for producing borinic acid derivative, and novel borinic acid derivative
IN2013CH05865A (en)
IL229669A0 (en) Process for preparation of 1,2,3 -triazole-4-carboxamides